A Phase 2 Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers
Latest Information Update: 18 Jul 2022
At a glance
- Drugs CBL-514 (Primary)
- Indications Obesity
- Focus Pharmacokinetics
- Sponsors Caliway Biopharmaceuticals
- 13 Jul 2022 Status changed from recruiting to completed.
- 08 Mar 2022 Planned End Date changed from 29 Apr 2022 to 1 Jun 2022.
- 08 Mar 2022 Planned primary completion date changed from 8 Apr 2022 to 1 Jun 2022.